Must Read: 10 Stocks Carl Icahn Loves in 2014
On CNBC's "Cramer's Stop Trading" segment, the co-manager of the Action Alerts PLUS portfolio said November seems too early for the company to reveal its results for Phase 1 testing of the drug, AG-120.
It seems too early, unless of course, the company has something that is going to be monumental in the future, Cramer added.
He noted that Celgene (CELG) has the marketing rights to the drug and also a large stake in Agios Pharmaceuticals.
-- Written by Bret Kenwell in Petoskey, Mich.